Imugene Limited - Our ESMO Asia 2019 poster presentation is now available for download http://ow.ly/NPEX50xhTvR | ASX: IMU #Oncology #BioTech #EndCancer #Immunotherapy #Cancer | Facebook
![DBPi at ESMO Congress'22 representing Prostate Cancer patient survey | DontBePatient Intelligence GmbH DBPi at ESMO Congress'22 representing Prostate Cancer patient survey | DontBePatient Intelligence GmbH](https://www.dontbepatient.com/dbp-data/uploads/esmo22.jpg)
DBPi at ESMO Congress'22 representing Prostate Cancer patient survey | DontBePatient Intelligence GmbH
![Presentato ad Esmo il poster sulla survey “Metastatic Breast Cancer: how and how often we communicate?” Presentato ad Esmo il poster sulla survey “Metastatic Breast Cancer: how and how often we communicate?”](https://www.incontradonna.it/index/media/k2/items/cache/77e3798bb9782084333898c5f75d9aab_XL.jpg)
Presentato ad Esmo il poster sulla survey “Metastatic Breast Cancer: how and how often we communicate?”
![Poster presented at ESMO 2018 Congress: 430P - Phase I study: Safety and tolerability of Varlitinib (VAR) in combination with Oxaliplatin and Capecitabine (COX) or Oxaliplatin and 5-FU (FOL) in advanced solid Poster presented at ESMO 2018 Congress: 430P - Phase I study: Safety and tolerability of Varlitinib (VAR) in combination with Oxaliplatin and Capecitabine (COX) or Oxaliplatin and 5-FU (FOL) in advanced solid](https://aslanpharma.com/wp-content/uploads/2018/10/ASLAN001-002SG-300x150.png)
Poster presented at ESMO 2018 Congress: 430P - Phase I study: Safety and tolerability of Varlitinib (VAR) in combination with Oxaliplatin and Capecitabine (COX) or Oxaliplatin and 5-FU (FOL) in advanced solid
![Anaveon announces poster presentation at the 2023 European Society for Medical Oncology Annual Meeting - anaveon Anaveon announces poster presentation at the 2023 European Society for Medical Oncology Annual Meeting - anaveon](https://anaveon.com/wp-content/uploads/2023/10/023-10-23-ESMO-2023-poster-ANV419-001-.png)
Anaveon announces poster presentation at the 2023 European Society for Medical Oncology Annual Meeting - anaveon
![VBI Vaccines Announces Biomarker Data from VBI-1901 Phase 1/2a Study in Recurrent GBM Presented at ESMO Virtual Congress 2020 - VBI Vaccines VBI Vaccines Announces Biomarker Data from VBI-1901 Phase 1/2a Study in Recurrent GBM Presented at ESMO Virtual Congress 2020 - VBI Vaccines](https://www.vbivaccines.com/wp-content/uploads/2020/09/ESMO-2020-Poster.png)